Gene one Inc
Gene one Inc
Problem Solution: Gene One Inc.
In this paper, the writer will attempt to show how the company, Gene One, made its decision to become a publicly traded company.
Gene One entered into the biotech industry with groundbreaking gene technology that eradicated disease in tomatoes and potatoes. This technology helped Gene One grow to a $400 million company in just eight years. Gene One has shown the seven competencies of being an effective leader, such as Emotional intelligence, Integrity, Drive, Leadership motivation, Self-confidence, Intelligence and Knowledge of the business. In order to keep pace with the demand and realize annual growth targets, Gene One believes going public within the next three years is the key to success.
Don Ruiz started Gene One at age thirty-seven; along with four colleagues, he recruited. Don Ruiz and his four colleagues share the same values and ethics about what is important in a variety of situations and allow their values to guide their decisions and actions.
Gene One hopes to realize growth targets, establish the company as a strong competitor, and show Wall Street it has the leadership and organizational capabilities to succeed as a public entity.
Gene One will become a transformational leader by implementing four elements: (1) Creating the Vision, reflect a future for the company; (2) Communicating the Vision, share the meaning and importance of the visionary goal to their employees and other stakeholder; 3) Modeling their vision, doing the things that symbolize the vision and (4) Building Commitment to that Vision, transforming their goal into reality.
Gene One will identify issues and turn them into opportunities.
Describe the Situation
Issue and Opportunity Identification
Gene One primary objective is to increase both revenue and profit through becoming a publicly traded company. They would also like to create a corporate culture conducive to growing the business. In attempting to obtain these objectives, Gene One faces several obstacles. This writer has identified the underlying issues below:
Gene One’s leadership, while at the forefront of the biotech sector, has no experience with the IPO process.
Gene One has to obtain additional funding to develop and introduce new products.
Gene One has to meet SEC, new management and board requirement to offer IPO’s.
Gene One has to communicate the IPO news to their employees.
Gene One has to identify two new technologies.
The use of a more state-of-the art process also incorporates appreciative inquiry, which helps to reframe the problem into an opportunity. Reframing the problem into an opportunity defines success in terms of the desired future end stated goals and factors for success.
Gene One must turn issues into opportunities and identify those opportunities in order to develop solutions. Below, this writer has identified some of the key opportunities for Gene One.
Gene One has the opportunity to turnover leadership to bring in new perspectives needed to build a new corporate culture.
Gene One has the opportunity to become an Industry Leader by offering IPO’s.
Gene One has the opportunity to succeed at balancing the power and politics affecting leadership ad the individual culture of the organization.
Gene One has the opportunity to establish this company as a strong competitor with new developments, advertising, and marketing.
Gene One has the opportunity to increase revenues by a minimum of 40 percent growth per year.
By maximizing the opportunities stated above, Gene One has an opportunity to become a publicly traded company; however, making the decision to offer IPO and implementing the above-stated opportunities will have ethical implications. Below this writer has identified different ethical dilemmas.
Stakeholder Perspectives/Ethical Dilemmas
Gene One will face some ethical dilemmas by implementing the opportunities this writer has written about in the previous section. The following ethical dilemmas are potentially present.
The Senior Leadership Team and Board Members. Don Ruiz, CEO has spoken to
Board member, John and board member, Susan. The board members have some doubt about members of the senior team’s ability to handle the task of the IPO process. Don